High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice. 2015

Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
Xiu-Hua Peng, Xiao-Nan Ren, Li-Xiang Chen, Bi-Sheng Shi, Chun-Hua Xu, Zhong Fang, Xue Liu, Jie-Liang Chen, Xiao-Nan Zhang, Yun-Wen Hu, Xiao-Hui Zhou, Shanghai Public Health Clinical Center, Key Laboratory of Medical Molecular Virology, Ministry of Education and Health, Fudan University, Shanghai 201508, China.

OBJECTIVE To optimize the viral persistence rate in a hydrodynamic injection (HI) based hepatitis B virus (HBV) transfection mouse model. METHODS (1) 5-6-wk-old male C3H/HeN and C57BL/6 mice were hydrodynamically injected with 10 μg endotoxin-free pAAV/HBV1.2 plasmid DNA via the tail vein. Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA, both in the serum and liver, were detected at different time points post HI by ELISA, immunohistochemical staining or quantitative polymerase chain reaction (PCR); (2) male C3H/HeN and C57BL/6 mice, either hydrodynamically injected mice at 10 wk post HI or naïve mice, were all immunized subcutaneously with 5 μg HBsAg formulated in complete Freund's adjuvant three times at a 2-wk interval. Two weeks after the final immunization, splenocytes were isolated for T cell function analysis by ELISPOT assay; and (3) five weeks post HI, C3H/HeN mice were intragastrically administered 0.1 mg/kg entecavir once a day for 14 d, or were intraperitoneally injected with 1 mg/kg interferon (IFN)-α twice a week for 2 wk, or were treated with PBS as controls. The sera were collected and assayed for HBV DNA on days 0, 7 and 14 after drug treatment. RESULTS (1) Approximately 90% (22/25) of the injected C3H/HeN mice were still HBsAg-positive at 46 wk post HI, whereas HBsAg in C57BL/6 mice were completely cleared at 24 wk. Serum levels of HBeAg in C3H/HeN mice were higher than those in C57BL/6 mice from 4 wk to 46 wk. HBV DNA levels in the hydrodynamically injected C3H/HeN mice were higher than those in the C57BL/6 mice, both in the serum (from 4 wk to 46 wk) and in the liver (detected at 8 wk and 46 wk post HI). Histology showed that hepatitis B core antigen and HBsAg were expressed longer in the liver of C3H/HeN mice than in C57BL/6; (2) HBsAg specific T cell responses after HBsAg vaccination in hydrodynamically injected C3H/HeN and C57BL/6 mice, or naive control mice were detected by ELISPOT assay. After stimulation with HBsAg, the frequencies of IFN-γ producing splenocytes in the hydrodynamically injected C3H/HeN mice were significantly lower than those in hydrodynamically injected C57BL/6 mice, control C3H/HeN and control C57BL/6 mice, which were 0, 17 ± 7, 18 ± 10, and 41 ± 10 SFCs/10(6) splenocytes, respectively, and the mean spot sizes showed the same pattern. Even just stimulated with PMA and ionomysin, T-cell responses elicited in the vaccinated control C3H/HeN were much higher than those in hydrodynamically injected C3H/HeN mice; and (3) For drug treatment experiments on the hydrodynamically injected C3H/HeN mice, serum HBV DNA levels in the entecavir treatment group declined (131.2 folds, P < 0.01) on day 7 after treatment and kept going down. In the group of IFN-α treatment, serum HBV DNA levels declined to a lowest point (6.42 folds, P < 0.05) on 7 d after treatment and then rebounded. CONCLUSIONS We have developed a novel HI-based HBV transfection model using C3H/HeN mice, which had a higher HBV persistence rate than the classic C57BL/6 mouse model.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006147 Guanine
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006513 Hepatitis B e Antigens A closely related group of antigens found in the plasma only during the infective phase of hepatitis B or in virulent chronic hepatitis B, probably indicating active virus replication; there are three subtypes which may exist in a complex with immunoglobulins G. HBeAg,Hepatitis B e Antigen,Hepatitis Be Antigen,e Antigen,e Antigens,HBe Ag-1,HBe Ag-2,Hepatitis Be Antigens,Antigen, Hepatitis Be,Antigen, e,Antigens, Hepatitis Be,Antigens, e,Be Antigen, Hepatitis,Be Antigens, Hepatitis
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia

Related Publications

Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
February 2024, Comparative medicine,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
July 2007, International journal of molecular medicine,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
January 2016, Methods in molecular biology (Clifton, N.J.),
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
January 2014, Antiviral research,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
October 2002, Proceedings of the National Academy of Sciences of the United States of America,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
January 2014, PloS one,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
December 2013, Molecular medicine reports,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
January 2016, PloS one,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
January 2014, PloS one,
Xiu-Hua Peng, and Xiao-Nan Ren, and Li-Xiang Chen, and Bi-Sheng Shi, and Chun-Hua Xu, and Zhong Fang, and Xue Liu, and Jie-Liang Chen, and Xiao-Nan Zhang, and Yun-Wen Hu, and Xiao-Hui Zhou
September 2014, Journal of virology,
Copied contents to your clipboard!